Eleftha (trastuzumab biosimilar) / Intas - LARVOL DELTA

Intas Pharma says its new biosimilar for breast cancer treatment is 65% cheaper (The Hindu Business Line) - "Drug-maker Intas Pharmaceuticals Ltd on Tuesday announced the launch of Trastuzumab biosimilar, Eleftha, that will bring down the cost of breast cancer treatment by nearly 65 per cent, the company claimed....The maximum retail price (MRP) of Eleftha will be ₹19,995 for the dose strength of 440 mg, which makes it nearly 65 per cent cheaper than the currently available options."

Biosimilar launch